Stock Financial Ratios

SRNE / Sorrento Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.10
Volume2,309,200.00
Market Cap ($M)0.12
Enterprise Value ($M)0.01
Book Value ($M)80.04
Book Value / Share1.57
Price / Book5.09
NCAV ($M)-225.43
NCAV / Share6.46
Price / NCAV-2.39
Income Statement (mra) ($M)
Revenue8.15
EBITDA-96.78
Net Income-63.94
Balance Sheet (mrq) ($M)
Cash & Equivalents38.32
Cash / Share0.76
Assets0.00
Liabilities346.48
Quick Ratio1.18
Current Ratio1.18
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.50
Return on Assets (ROA)-0.16
Return on Equity (ROE)-0.80
Identifiers and Descriptors
CUSIP83587F202
Central Index Key (CIK)850261
Industry Groups
SIC 8731 - Commercial Physical and Biological Research
Other Related CUSIPS
83587F952
83587F103
83587F902
Share Statistics
Common Stock Shares Outstanding50,882,856
Weighted Average Number Of Diluted Shares Outstanding50,360,000
Preferred Stock Shares Outstanding0
Weighted Average Number Of Shares Outstanding Basic50,360,000
Common Shares Outstanding50,887,102
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Intangibles Per Share0.00
Cash And Equivalents Per Share0.75
Accumulated Depreciation And Depletion Per Share0.00
Long Term Debt Per Share0.49
Liabilities Per Share6.88
Cash Per Share0.76
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Assets Current Per Share0.88
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Equity Per Share2.57
Debt Per Share0.53
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00

Peers - Commercial Physical and Biological Research (8731)

SRNE : Sorrento Therapeutics Stock Analysis and Research Report

At its core, Sorrento Therapeutics is an antibody-centric company and leverage its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. The company's validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others. The company's vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as TCR-like antibodies. With LA Cell, Inc. (“LA Cell”), its joint venture with City of Hope, its objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, Sorrento Therapeutics has acquired and are assessing the regulatory and strategic path forward for its portfolio of late ...

Click for full article

Related News Stories

Sorrento Therapeutics: Will This Novel CAR-T Deliver Robust Value?

2018-02-23 seekingalpha
The wise investor can profit if he can think independently of the crowd and reach the rich answer when the majority of financial opinion is leaning the other way. - The Father of Growth Investing (Philip Fisher) (97-1)

Space Entrepreneur Peter Diamandis Is Trying to Extend People's Lifespans--Using Placentas | Inc.com

2018-02-21 inc
We notice you're visiting us from a region where we have a local version of Inc.com. (16-0)

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

Peter Diamandis' Celularity could help cure cancer, extend lifespans

2018-02-15 cnbc
A new biotech start-up Celularity is mining the human placenta for stem cells to use in new applications, including helping cancer patients and extending human life. (29-4)

Week In Review: C-Bridge Raising Another $650 Million For China Healthcare

2018-02-04 seekingalpha
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million. Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million. C-Bridge focuses on PE capital because it believes later-stage companies are currently the most promising investment sector in China healthcare. The company emphasizes China investments, but considers itself a global investor. (35-1)

CUSIP: 83587F202